We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Genotyping Performed by FRET-PCR Without DNA Extraction

By LabMedica International staff writers
Posted on 07 Jul 2014
Image: The LightCycler 2.0 real-time polymerase chain reaction analyzer and centrifuge (Photo courtesy of Roche).”
Image: The LightCycler 2.0 real-time polymerase chain reaction analyzer and centrifuge (Photo courtesy of Roche).”
Image: The Scepter 2.0 Automated Cell Counter (Photo courtesy of Merck Millipore).
Image: The Scepter 2.0 Automated Cell Counter (Photo courtesy of Merck Millipore).
Blood samples are extensively used for the molecular diagnosis of many hematological diseases using a variety of techniques, based on the amplification of nucleic acids.

Current methods for polymerase chain reaction (PCR) use purified genomic DNA, mostly isolated from total peripheral blood cells or white blood cells (WBC), which can be improved by a real-time fluorescence resonance energy transfer-based method for genotyping directly from blood cells.

Hematologists at the Hospital Universitari Son Espases (Palma de Mallorca, Spain) studied peripheral blood from 34 patients collected into tubes containing ethylenediaminetetraacetic acid (EDTA). Among the samples, they included a mixture of mutant alleles for patients suffering from thrombosis or hereditary hemochromatosis. Red blood cells (RBCs) were lysed and white blood cells (WBCs) isolated. A real-time PCR was then performed followed by a melting curve analysis for different genes including methylenetetrahydrofolate reductase (MTHFR), hemochromatosis (HFE), coagulation factor V Leiden (F5), prothrombin factor two (F2) and coagulation factor XII (F12).

The real time PCR was performed on the LightCycler 2.0 Instrument (Roche Diagnostics Corporation, Indianapolis, IN, USA). In order to standardize the samples for the real-time PCR reaction, cells were counted in a Scepter 2.0 Automated Cell Counter (Merck Millipore, Billerica, MA, USA) and adjusted to 5×106 cells/mL. After testing 34 samples comparing the real-time crossing point (CP) values between 5×106 WBC/mL and 20 ng/µL of purified DNA, the results for F5 Leiden were as follows: CP mean value for WBC was 29.26 ± 0.57 versus purified DNA 24.79 ± 0.56. There was an observed delay of about four cycles when PCR was performed from WBC instead of DNA.

The authors concluded that their protocol obviates the DNA purification stage, thereby saving time and resources. Furthermore, since the manipulation performed on the sample is minimal, it may decrease the risk of contamination. As they reported the results from a variety of genes, they contend that their protocol will be suitable for the genotyping of almost any inherited polymorphism. The study was published on June 25, 2014, in the Journal of Blood Medicine.

Related Links:

Hospital Universitari Son Espases
Roche Diagnostics Corporation
Merck Millipore


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automatic CLIA Analyzer
Shine i6000
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT

Channels

Clinical Chemistry

view channel
Image: Two major international studies identified noninvasive tests that can accurately diagnose and assess MASLD and MASH, reducing reliance on liver biopsy. (Image Credit: Adobe Stock)

Noninvasive Tests Offer Alternatives to Biopsy for Assessing Advanced Liver Scarring

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects up to one in three adults worldwide and as many as seven in 10 people with obesity or type 2 diabetes. Its more severe form, metabolic... Read more

Molecular Diagnostics

view channel
Image:Graphical Abstract (Victori P, Hua K, Twigger AJ, et al. Tumor digital twins uncover therapeutic strategies in triple-negative breast cancer. Cell Reports Medicine, 2026. doi:10.1016/j.xcrm.2026.103119.)

Digital Twins Predict Treatment Response in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive, fast-growing subtype that accounts for about 15% of all breast cancer cases. Its tumor cells lack estrogen receptors, progesterone receptors, and... Read more

Microbiology

view channel
Image: Graphical Abstract (Andrew Medina-Marino, Chibuzor M Babalola, Mandisa M Mdingi, et al. Clinical Infectious Diseases, 2026. doi:10.1093/cid/ciag577.)

Repeat Prenatal STI Screening and Treatment May Reduce Preterm Births

Preterm birth remains a major obstetric concern and is associated with serious complications in early childhood. Common sexually transmitted infections during pregnancy often cause no symptoms, making... Read more

Pathology

view channel
Image Credit: Adobe Stock

AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification

In early-stage breast cancer, precision oncology relies on biological information to guide personalized treatment decisions. Because access to tissue-based genomic testing may be limited, there is growing... Read more